Changing_the_Deal.xls
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAMAN
1
Original Deal SnapshotOriginal Deal DateRestated SnapshotRestated Deal DateR&DClientStage at RestatementType of Change(s) in Restated DealKey Changes Made in Restated AgreementDeal TypesDeal Size ($M)Maximum Share (%)Termination DateExclusivityDeal SubjectUpfront Cash ($M)Upfront Equity ($M)Contingent Equity ($M)R&D Support ($M)FTE Rate ($M)Loan ($M)Dev / Reg Milestones ($M)Other Milestones ($M)Total Precommercial Payments ($M)Sales Milestones ($M)Deal Size ($M)EFR$200M (%)EFR$500M (%)EFR$1B (%)Maximum Royalty (%)Marketing Fee (%)Transfer Price (%)Manufacture Cost + (%)Profit Split (%)DiseaseIndicationTechnologySub-TechnologyTerritoryFinancial Term Explanations
2
Commercial Alliances:
3
Link10/2010Link7/2012Amicus TherapeuticsGlaxoSmithKlinePhase III, Phase II, PreclinicalDev Cost; Milestones; Royalty; Territory20% co-dev to 40% by Amicus; $93.5M dev milestones to $3.5M; $80M sales milestones to $0; 14-19% royalty to royalty-free; Worldwide to Ex-USCo-Development, Equity, License, Restatement, Termination 22.10 11/2013ExclusiveAmigal (migalastat) & combinations for Fabry disease ex-US 18.60 0.30 3.50 22.10 22.10 Endocrinological & MetabolicLysosomal Storage DisordersSyntheticsSmall MoleculeAfrica, Asia, Europe, Middle East, NAFTA, South America2.95M shs @ $6.30/sh (107% of FMV) per 7/17/12 PR | GSK sales are royalty-free; Amicus has 5% royalty on Co-Formulation Product in US
4
2/20096/2012AmpliPhi BiosciencesCelladonPhase IIMilestones; Royalty$20M dev milestones to $0; 10% royalty to royalty-freeLicense, RestatementExclusiveMydicar (AAV/Serca2) for congestive heart failureCardiovascularCongestive Heart FailureOligonucleotidesGene TherapyWorldwideroyalty-free | no milestone payments
5
10/20006/2011RespireRx PharmaceuticalsServierLead MoleculeUpfront; Milestones; Royalty; TerritoryAdd'l $1M upfront plus $2M in add'l milestones for expanded territory to worldwide (was ex-NA, SA & Oceania); from royalty-free to 2.25% royaltyLicense, Option, Research, Supply 3.88 2.25 ExclusiveAmpakine (CX1632) to treat neurodegenerative diseases ex-NA, SA & Oceania 1.00 0.88 2.00 3.88 3.88 2.25 2.25 2.25 2.25 Central Nervous System, PsychiatricAlzheimer's Disease, Anxiety, DementiaSyntheticsSmall MoleculeAfrica, Asia, Europe, Middle East$2M if Servier exercised assignment option
6
Link2/2007Link11/2010Arbor Pharmaceuticals, XenoPortGlaxoSmithKlinePhase III, FormulationMilestones; Royalty; Profit Split if CoPromote; Territory$160M neuropathic pain milestones to $200M; 10% royalty (< $500M/yr) if no PS to 15-30%; 20% PS (<$750M/yr) to 20-50% PS; WW ex-Asia to US onlyCo-Development, Co-Promotion, Equity, License, Restatement, Termination 645.00 50.00 11/2012ExclusiveHorizant (gabapentin enacarbil) for pain & restless leg syndrome in US 40.00 115.00 200.00 355.00 290.00 645.00 15.63 20.75 25.38 30.00 50.00 Central Nervous SystemOther Central Nervous System, PainDrug DeliveryOral, Sustained ReleaseNAFTA20M eq on 11/12 termination, plus add'l $20M eq put | 15-30% US royalty in event XenoPort doesn't co-promote | $115M for RLS | 20-50% US P/L split if XenoPort co-promotes, increasing with annual sales
7
8/20039/2010ProcomSomaxon (now Pernix Therapeutics)ApprovedFieldNarrowed the range of Doxepin dosage deemed to be Licensed ProductLicense, Restatement 5.00 ExclusiveDoxepin, amitriptyline, trimipraline, Trazodone & nortriptyline for insomnia 5.00 5.00 5.00 5.00 Central Nervous SystemSleep DisordersSyntheticsSmall MoleculeWorldwide
8
Link6/2004Link10/2009Vanda PharmaceuticalsNovartisApprovedRole Reversal in NA; Upfront; Milestones; RoyaltyWas $0.5M upfront, $17.5M dev & $75M sales milestones plus 25% royalty by Vanda for WW rights; to regain NA, Novartis paid $200M upfront, $40M dev & $225M sales milestones plus 10-16% royaltyEquity, License, Restatement, Settlement, Termination 490.00 16.00 12/2014ExclusiveFanapt (iloperidone) for schizophrenia in NA 200.00 25.00 40.00 265.00 225.00 490.00 10.00 11.00 13.00 16.00 PsychiatricSchizophreniaSyntheticsSmall MoleculeNAFTA$25M equity purchased by Novartis in connection with 12/14 termination and settlement
9
Link6/2007Link7/2009Zalicus (now Epirus Biopharmaceuticals)Fovea PharmaceuticalsPhase IField; Milestones; RoyaltyDropped royalty-free Combinations field; $20M dev milestones to $24.75M; $10M add'l milestone to $15M; $25M sales milestones added; all royalty tiers increased by 1%Co-Development, License, Restatement 64.75 12.00 ExclusiveFOV 1801 (prednisporin) for glaucoma ex-NAFTA, S Korea & Singapore 24.75 15.00 39.75 25.00 64.75 4.00 5.60 8.00 12.00 OphthalmicGlaucomaSyntheticsCombinatorialAfrica, Asia, Europe, Middle East, South America$15M if approved for keratoconjunctivitis sicca | 4-12% for Licensed Products (worldwide); royalty-free for Collaboration Combinations in each party's respective territory
10
Link12/2005Link5/2009XenoPort (now Arbor Pharmaceuticals)Astellas PharmaPhase IIIRoyalties; Supply13-15% royalties to 15% base plus up to 3% based on NHI price; supply (@ manu cost plus 25%) transferred to AstellasCo-Development, License, Restatement 85.00 18.00 ExclusiveRegnite (XP13512 gabapentin) for neuropathic pain in Japan, Korea, Taiwan & ASEAN 25.00 40.00 20.00 85.00 85.00 15.00 15.00 15.00 18.00 Central Nervous SystemPainSyntheticsSmall MoleculeAsia15% Basic Royalty Rate, plus up to 3% depending on NHI Price in Japan
11
12/20042/2009AmpliPhi BiosciencesCelladonPhase IDev Cost; Milestones; Royalty; SupplyCoDev to License only; $11.5M dev milestones to $20M; 20-25% PS to 10% royalty; full to no supplyLicense, Restatement, Termination 23.70 10.00 6/2012ExclusiveMydicar (AAV-based calcium release in sarcoplasmic reticulum) for congestive heart failure 3.70 20.00 23.70 23.70 10.00 10.00 10.00 10.00 CardiovascularCongestive Heart FailureOligonucleotidesGene TherapyWorldwide10%, subject to a buy-down to 5% for $50M | $3.7M for manu process dev (see Supply agmt)
12
3/19991/2009Sanofi, GenzymeExact SciencesDiagnosticMilestones; RoyaltyWas $250K dev milestones & now $1.5M dev & $3M sales milestones; was 3% royalty & now 5-7.5%, depending on priceDevelopment, License, Research 4.65 7.50 Non-exclusiveStool-based disease detection, colorectal cancer screening 0.15 1.50 1.65 3.00 4.65 7.50 Cancer, UnlimitedColorectalDiagnostics, ScreeningWorldwide$150K per 7/99 original agmt | 5-7.5%, depending on volume and price
13
3/20077/2008Cambridge HeartSt. Jude Medical (now Abbott)DeviceExclusivity; Marketing FeeWas semi-exclusive for 20% agent fee; now non-exclusive marketing representative (no agent fee); no more board observer rightsCo-Market, RestatementNon-exclusiveHearTwave implantable ECG measurement system in NAFTACardiovascularDiagnosis - Contrast/ImagingDeviceNAFTA
14
Link2/2004Link7/2008XomaNovartis, ChironPhase ICo-Dev; Field; Milestones; RoyaltyWas Co dev, $50M loan & 30% PS for 4 Mabs; now no co-dev, $14M milestones & 10-18% royalty for two MabsDevelopment, License, Loan, Restatement, Supply 27.70 18.00 ExclusiveHCD122 (hu MAb to CD40) and X213 (hu MAb to Prolactin rec) for lymphoma & multiple myeloma 13.70 7.00 7.00 27.70 27.70 10.00 11.20 14.10 18.00 CancerLymphoma, Multiple MyelomaMonoclonalsHuman AbsWorldwide$6.2M cash plus $7.5M reduction of outstanding balance under loan agmt | Novartis pays Xoma's FTEs for process dev on X213 (LFA102) manu process (see supply contract)
15
2/20029/2007Nucryst PharmaceuticalsSmith & NephewDeviceRoyalty; Transfer PriceWas 7.5% Distribution Royalty & Manu Cost, plus up to 12.5% add'l based on GM; now 7.5% Distribution Royalty plus 7.5% Transfer Price, or 15% royalty if S&N suppliesAsset Purchase, Co-Development, License, Supply 52.50 15.00 ExclusiveActicoat (nanocrystaline silver antimicrobial coating) as burn dressing 7.50 7.50 45.00 52.50 15.00 DermatologicBurns, Wound HealingDrug DeliveryOtherWorldwide15% royalty if Nucryst is not supplying Product
16
10/20047/2007Novadel PharmaTalon Therapeutics (now Spectrum Pharmaceuticals)Preclinical, FormulationMilestones; RoyaltyNDA approval milestones reduced from $6.5M to $5M; eliminated 50% reduction of royalty rates until recovery of Licensee's dev costs via Sublicensee FeesDevelopment, Equity, License, Supply 11.50 25.00 ExclusiveZensana (ondansetron oral spray) to prevent chemo nausea & vomiting in NA 11.50 CancerOther CancerDrug DeliveryOralNAFTA
17
Link3/2002Link7/2007The Medicines CompanyNycomed PharmaFiledMilestones; Transfer Price; UpfrontWas $2.5M indication milestone & 50% Transfer Price to TMC; now TMC pays $40M at restatement, $5M indication milestone & 12.5% Transfer Price for Nycomed's distribution servicesDistribution, Equity, Termination 5.00 50.00 7/2007ExclusiveAngiomax (bivalirudin) as thrombin inhibitor in Europe 5.00 CardiovascularRestenosisEurope
18
Link1/2006Link6/2007Zalicus (now Epirus Biopharmaceuticals)Fovea PharmaceuticalsDiscoveryDev Cost; TerritoryWas worldwide license w co-dev option for combination products; now independent dev of collab product by territoryCo-Development, License, Research, Restatement, Termination 30.00 11.00 7/2009ExclusiveCytokine modulator combinations for ophthalmic diseases ex-NAFTA, Singapore & S. Korea 20.00 10.00 30.00 30.00 3.00 4.60 7.00 11.00 OphthalmicBroad Focus OphthalmicSyntheticsCombinatorialAfrica, Asia, Europe, Middle East, South America3-11% for Licensed Products (worldwide); royalty-free for Collaboration Combinations in each party's respective territory
19
Link12/2002Link4/2007Eyetech (now Astellas Pharma)PfizerApprovedDev Cost; Milestones; Royalty; TerritoryEach pays 100% of specific ongoing trials; WW to ex-US & dropped milestones, royalty, co-promote & profit splitCo-Development, License, Restatement, SupplyExclusiveMacugen (VEGF inhib) for age ­related macular degeneration and diabetic macular edema ex-USOphthalmic
Age-Related Macular Degeneration, Other Ophthalmic
OligonucleotidesLigandsAfrica, Asia, Europe, Middle East, NAFTA, South Americaeach pays 50% of FBMC under Degussa agmt | each pays for clinical trials in its Territory | royalty-free to both parties
20
5/20064/2007INEX Pharmaceuticals (now Arbutus Biopharma)Hana Biosciences (now Spectrum Pharmaceuticals)Phase II, Preclinical, FormulationFieldRestatement excludes MD Anderson patents from LicenseEquity, License 42.00 10.00 Exclusive­ Marqibo (vincristine), Alocrest (vinorelbine) & Brakiva (topotecan) liposomal dev for cancer 42.00 CancerBroad Focus CancerDrug DeliveryLiposomesWorldwide
21
Link8/2004Link2/2007Halozyme TherapeuticsBaxterApproved, FormulationUpfront; Equity; Milestones; Royalty; TerritoryWas 50% PS for US only; now $10M upfront, $20M eq, $25M milestones & 30% TP for worldwideDistribution, Restatement, Supply 55.00 30.00 ExclusiveHylenex human PH20 hyaluronidase for improved drug absorption 10.00 20.00 5.00 35.00 20.00 55.00 30.00 UnlimitedAdjuvant, Drug Delivery, Recombinant DNAOtherWorldwide$10M on Restatement date | $20M for 2.07M shares in 2/07, per Halozyme's 2007 10-K
22
Link9/2003Link7/2006AlnylamMerckDiscoveryDev Cost; Field; Milestones; RoyaltyWas no R&D funding, $2M milestone & 5-8% US royalty on Merck Products; now 50% US co-dev @ $485K/FTE, 9 Merck targets & 1 excluded, $5.5M co-dev, $30.5M opt-out & $41M Merck milestones, 5-10% US royalty on Merck Products (for co-dev: same 50% PS US & 10-15% ex-US)Co-Development, Co-Promotion, License, Option, Research, Restatement, Termination 84.50 50.00 9/2007ExclusiveRNAi for nine non-druggable targets 0.49 41.00 43.50 84.50 84.50 10.00 11.40 13.00 15.00 50.00 UnlimitedOligonucleotidesRNAiWorldwide10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products
23
Link6/1998Link7/2006AradigmNovo NordiskPhase III, FormulationCo-dev; Milestones; RoyaltiesWas co-dev with 11% PS; now Novo pays all dev & lower royalty only (no milestones)Assignment, Equity, License, Loan, Restatement 29.10 5.30 ExclusiveAERx insulin Diabetes Management System for inhaled insulin 20.00 1.60 7.50 29.10 29.10 5.30 Endocrinological & MetabolicDiabetesDrug DeliveryOtherWorldwide$1.6M via loan conversion in 7/10 | 3.25-5.3% royalty on First Product, depending on sales Baseline and years from launch; 4.25-5.3% royalty on any Later Product | $7.5M loan (converted to $9.1M of equity in 7/10)
24
Link6/2000Link7/2006King PharmaceuticalsWyeth (now Pfizer)ApprovedMarketing Fee; Milestones; TermTerm was until 10/08, extended until 12/10; was 15-52.5% promotion fee, with 25% residual for 2 yrs; now 30-14% promotion fee with no residualCo-Promotion, Restatement 170.00 52.50 ExclusiveAltace (ramipril) ACE inhibitor in US 75.00 75.00 150.00 20.00 170.00 52.50 CardiovascularHypertensionSyntheticsSmall MoleculeNAFTA15-52.5% for 2006; 30% for 2007; 22.5% for 2008; 14.2% for 2009; 25% for 2010 but $5M max | $75M at signing (see separate analysis) | $75M eq at signing (see separate analysis)
25
Link1/2004Link7/2006ArchemixARCA BiopharmaPreclinicalUpfront; Co-Dev; Equity; Milestones; RoyaltyWas $3M upfront, $4M R&D then 50/50 co-dev, $10M milestone & 50/50 PS; now $4M upfront, $10M eq at IPO, $5M R&D funding, $35M milestones, 6-10% royalty with 25% co-dev option for 25% PSCo-Development, Equity, License, Option, Restatement 54.25 10.00 ExclusiveARC183 thrombin inhibitor for use in coronary artery bypass graft surgery 4.00 10.00 5.25 0.37 35.00 54.25 54.25 6.50 7.60 7.80 10.00 25.00 Cardiovascular
Atherosclerosis/Coronary Artery Disease, Other Cardiovascular
OligonucleotidesLigandsWorldwideArchemix has option to co-dev by reimb 25% of all prior and on-going dev costs plus milestones; then receive 25% PS of all Product sales | $10M equity at Archemix' IPO
26
6/19994/2006EUSA Pharma, Jazz Pharmaceuticals, CytogenProgenics PharmaceuticalsDiscoveryBuyout; Milestones; Royalty; TerritoryWas 50% PS for NA; now $13.2M buyout payment by Progenics, $7M dev & $45M sales milestones, and 2-5% royalty for worldwide rightsAsset Purchase, Joint Venture, License, Termination 5.10 50.00 4/2006ExclusivePSMA LLC for prostate cancer 5.10 CancerProstateVaccinesWorldwide
27
Link8/2003Link2/2006Memory PharmaceuticalsRochePreclinicalField; Milestones; RoyaltyAdded 2 types of Compound; Added $53M dev & $17.5M sales milestones for new Compounds; lowered royalty tiers for new CompoundsCo-Development, Co-Promotion, License, Restatement, Termination 211.20 18.00 12/2010ExclusiveMEM 3454 (nicotinic alpha-7 agonist) for neuro & psychiatric disorders 28.00 105.70 133.70 77.50 211.20 9.00 9.00 10.00 18.00 20.00 Central Nervous System, Psychiatric
Alzheimer's Disease, Broad Focus Central Nervous System, Broad Focus Psychiatric, Schizophrenia
SyntheticsSmall MoleculeWorldwide$28M for MEM3454 for Neuro | $53M for MEM3454 for other; $30M for Memory Products; $22.7M for Collaboration Products | 20% of US gross profits if pays 15% of Ph III global dev costs plus 25% of US marketing costs
28
9/200112/2005LillyInterMune (now Targanta Therapeutics)Phase IIUpfront; Milestones; RoyaltyWas $50M upfront, $95M in dev milestones plus 22-27% royalty to Lilly; now $1M upfront, $20M dev & $15M sales milestones plus 10-18% royalty to Lilly Asset Purchase, Development, License, Research 145.00 27.00 ExclusiveOritavancin (LLY 333328) glycopeptide as antibiotic 10.00 10.00 20.00 15.00 145.00 10.00 12.40 15.20 18.00 Infectious-BacterialBroad Focus Infectious-BacterialPeptidesWorldwide
29
Link10/2003Link10/2005PDL BioPharmaRochePhase IIField; Upfront; MilestonesWas $17.5M upfront, $187M milestones, 50% PS in US & 17.5-30% royalty ROW; added chronic transplant field for add'l $10M upfront and add'l $117.5M milestonesCo-Development, Co-Promotion, License, Restatement, Supply, Termination 367.50 50.00 8/2006Exclusive2nd Generation Zenapax (daclizumab s.c.) for asthma and chronic transplant treatment 27.50 0.23 122.50 117.50 267.50 100.00 367.50 18.75 24.00 27.00 30.00 50.00 Respiratory, Transplantation
Asthma, Organ/Tissue Transplants, Other Transplantation
MonoclonalsHumanized AbsWorldwide$17.5M in 9/04, plus $10M at 10/05 restatement | $65M for asthma, plus $35M for chronic transplant | equal sharing of clinical costs | Roche pays 17.5% to 30% for ex-US | $122.5M for asthma | $117.5M for chronic transplant | PDL pays Roche 50% of Gross Margin in US for Asthma; Roche pays PDL 50% of Gross Margin in US for Transplant
30
Link4/1995Link7/2005COR Therapeutics (now Takeda)Schering-Plough (now Merck)ApprovedUpfront; Royalty; TerritoryWas 50% PS in NA & Europe; now add'l $35.5M and 24-32% royaltyLicense, Restatement, Supply 35.50 32.00 ExclusiveIntegrelin (Eptifibatide) for restenosis, acute MI & angina 35.50 35.50 35.50 25.00 28.80 30.40 32.00 CardiovascularAngina, Myocardial Infarction, RestenosisPeptidesWorldwideMPI supplies at FBMC through 3rd party vendors, subject to Put/Call (see 9/05 supply agmt)
31
Link11/2003Link7/2005PPD (now Furiex)TakedaPhase II, PreclinicalRole Reversal; Upfront; Milestones; RoyaltyWas $40M equity, $17.5M milestones to Syrrx and 540% PS; now Takeda (acq. Syrrx) has worldwide rights for $15M upfront, $85.5M dev & $33M sales milestonse, plus 3-12% royaltyDevelopment, License 133.50 12.00 ExclusiveNesina (alogliptin DPP4 inhibitor) for type 2 diabetes 15.00 85.50 100.50 33.00 133.50 7.00 7.00 8.00 12.00 Endocrinological & MetabolicDiabetesDrug Delivery, SyntheticsOral, Small MoleculeWorldwide7-12% in US; 4-8% in EU & Japan; 3-7% in ROW
32
Link2/2004Link5/2005XomaChiron (now Novartis)DiscoveryField; RoyaltyWas 30% PS to Xoma for two targets; now 22.5% PS until dev cost repayment, with third target addedCo-Development, Co-Promotion, License, Loan, Option, Research, Termination 60.00 30.00 7/2008ExclusiveCD40, M-CSF, MN & EphB3 Mabs for cancer 10.00 0.28 50.00 60.00 60.00 30.00 CancerBroad Focus CancerMonoclonalsHuman AbsWorldwideXoma funds 30% Chiron 70% | $50M loan facility (see separate contract) | 22.5-30% PS to Xoma, with lower rate paid until $15M differential utilized (or reduced via milestones accomplished)
33
Link12/1997Link2/2005MedImmune (now AstraZeneca)AbbottApproved, Phase IIICo-Promotion; Field; RoyaltiesNumax added in 2/05; transfer price increased to 60%; MedI has co-promotion rights in TerritoryCo-Development, Co-Promotion, Distribution, Restatement 60.00 ExclusiveSynagis (palivizumab) and Numax (MEDI-524) for RSV ex-US 60.00 50.00 Infectious-ViralRespiratory Syncytial Virus/RSVMonoclonalsHumanized AbsAfrica, Asia, Europe, Middle East, NAFTA, South America52.5% up to Threshold & 60% above Threshold; Threshold is $400M unless Numax is dropped, then $200M
34
1/19991/2005Symyx (now Accelrys)Dow ChemicalOtherDev Cost; RoyaltiesWas $14.9M in R&D funding over 3 yrs, and 2.5% royalty; now $120M in R&D funding over 5 yrs, and 0.12% to 4.9% royalty (based on value-added)License, Research, Restatement 120.00 4.90 ExclusiveSolution polymerization of olefins 70.00 50.00 0.46 120.00 120.00 4.90 Other/MiscellaneousIndustrial chemicalsSyntheticsCombinatorialWorldwide$7M/yr for Tools, $4M/yr for access , $3M/yr for Software, all for 5 yrs | $50M in R&D support over 5 yrs | 0.12% to 4.91% royalty, based on 25% of Added Value
35
36
University Licenses:
37
8/20068/2011Johns HopkinsRosetta GenomicsLead MoleculeRoyaltyDecreased from $100K/yr to $10K/yr for 6th anniversary of signing onwardLicense 0.13 4.00 Non-exclusiveHuman miRNAs and their evaluation with Dicer KOs 0.13 0.13 4.00 4.00 4.00 4.00 UnlimitedOligonucleotidesRNAiWorldwide
38
6/20063/2009Max Planck InstituteRosetta GenomicsDiagnosticStacking; Sublicensee RevStacking offset now applies only if obligations exceed 15% cumulative royalty; sublicense rev share was 20%; now 25% with 12.5% anti-stacking floorLicense 0.40 6.00 Semi-exclusiveSmall expressed RNA molecules 0.40 0.40 UnlimitedOligonucleotidesRNAiWorldwide
39
11/200010/2008UC San FranciscoNeurogesXPreclinicalMilestones; RoyaltyWas $1.15M milestones & 1% royalty; now no milestones and 0.5% royaltyDevelopment, License 0.50 Exclusivehigh dose capsaicin for neuropathic pain 0.50 Central Nervous SystemPainDrug DeliveryTopicalWorldwide
40
7/20047/2007Tel Aviv UniversityBrainStorm Cell TherapeuticsLead Molecule, Orphan IndicationRoyalty; Sublicensee Rev; TermWas 5% royalty for latest of patents, 15 yrs from FCS or Orphan Status, plus 30% sublicense rev; now drops to 3% if no patent or Orphan Status, plus 25% sublicense rev through Phase II and 20% after Phase II completionEquity, License, Research 1.24 5.00 ExclusiveTransformation of bone marrow and cord blood stem cells into neuron-like and glial-like cells 0.10 1.14 1.24 1.24 5.00 5.00 5.00 5.00 Central Nervous SystemParkinson's DiseaseCell Therapy - Stem Cells/FactorsWorldwide
41
6/20015/2007Oregon Health & Science UniversityNovacea (now Paratek Pharmaceuticals)PreclinicalField; Net Sales deductionsWas oncology and other disease therapies & now all uses, including diagnostics and prophylactics; elaborated definition of Net Sales deductionsDevelopment, Equity, License 12.75 2.50 ExclusiveVitamin D for treatment of tumors and other hyperproliferative disorders 12.00 0.75 12.75 12.75 2.50 2.50 2.50 2.50 CancerSolid TumorsWorldwide
42
7/20025/2007University of PittsburghNovacea (now Paratek Pharmaceuticals)Phase IDiligence; AssignmentAdded CRE definition, permitted non-financial redactions of sublicense terms, and allowed assignment by first level sublicenseeEquity, License 0.10 2.00 ExclusiveCombination chemotherapy 0.10 0.10 2.00 2.00 2.00 2.00 CancerBroad Focus CancerWorldwide
43
8/19982/2007Women and Children's HospitalBioMarinLead Molecule, Orphan IndicationDiligence; Net Sales deductions; TermDev Diligence dropped; added elaborated defintion of Net Sales deductions; License/royalty was 10 yrs from 8/98 & now extends until 12/31/23License 0.10 5.00 Exclusiverh N-acetylgalactosamine 4 Sulfatase for ERT for Lysosomal Storage Disease MPS IV 0.10 Other/MiscellaneousGenetic DisordersRecombinant DNAWorldwide
44
10/20019/2006UC Los AngelesStemSource (now Cytori)Lead MoleculeMilestones; Royalty; Sublicensee RevWas $225K milestones, 10% royalty on gene/cell therapy (3% other) & 25% of sublicensee rev; now no milestones, 4% royalty and 15% of sublicensee revDevelopment, License 1.08 10.00 Exclusiveadipose-derived connective tissue stem cells for therapeutic application 0.48 1.08 4.00 4.00 4.00 4.00 Dermatologic, Other/MiscellaneousCosmetics, Wound HealingCell Therapy - Stem Cells/FactorsWorldwide
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
Main menu